Pharmigene Balance Sheet Health
Financial Health criteria checks 1/6
Pharmigene has a total shareholder equity of NT$390.4M and total debt of NT$594.4M, which brings its debt-to-equity ratio to 152.2%. Its total assets and total liabilities are NT$1.0B and NT$634.2M respectively.
Key information
152.2%
Debt to equity ratio
NT$594.40m
Debt
| Interest coverage ratio | n/a |
| Cash | NT$124.52m |
| Equity | NT$390.44m |
| Total liabilities | NT$634.25m |
| Total assets | NT$1.02b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 7595's short term assets (NT$223.2M) exceed its short term liabilities (NT$36.4M).
Long Term Liabilities: 7595's short term assets (NT$223.2M) do not cover its long term liabilities (NT$597.8M).
Debt to Equity History and Analysis
Debt Level: 7595's net debt to equity ratio (120.3%) is considered high.
Reducing Debt: 7595's debt to equity ratio has increased from 6.3% to 152.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 7595 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 7595 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 63.8% each year